TY - JOUR T1 - Human leukocyte antigen susceptibility map for SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.03.22.20040600 SP - 2020.03.22.20040600 AU - Austin Nguyen AU - Julianne K. David AU - Sean K. Maden AU - Mary A. Wood AU - Benjamin R. Weeder AU - Abhinav Nellore AU - Reid F. Thompson Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/26/2020.03.22.20040600.abstract N2 - We probe how genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen [HLA] A, B, and C) may affect susceptibility to and severity of severe acute respiratory syndrome 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We execute a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across all known HLA -A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explore the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome is successfully sampled and presented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (1). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting it could enable cross-protective T-cell based immunity. Finally, we report global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic.IMPORTANCE Part of why the immune response to a virus differs across individuals is explained by genetic variation, especially in the HLA genes. Understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could thus improve assessment of viral severity in the population. In the event of the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, high-risk individuals could be prioritized for vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRFT was supported by the U.S. Department of Veterans Affairs under award number 1IK2CX002049-01, and the Sunlin & Priscilla Chou Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code available at https://github.com/pdxgx/covid19. Raw sequence data available through https://www.ncbi.nlm.nih.gov/refseq/. https://github.com/pdxgx/covid19 ER -